Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 101
Filtrar
1.
Sci Rep ; 10(1): 6478, 2020 04 15.
Artículo en Inglés | MEDLINE | ID: mdl-32296104

RESUMEN

Despite improvements in surgery and medical treatments, epithelial ovarian cancer (EOC) remains the most lethal gynaecological malignancy. Aim of this study is to investigate the preclinical immunotherapy activity of cytokine-induced killer lymphocytes (CIK) against epithelial ovarian cancers, focusing on platinum-resistant settings. We generated CIK ex vivo starting from human peripheral blood samples (PBMCs) collected from EOC patients. Their antitumor activity was tested in vitro and in vivo against platinum-resistant patient-derived ovarian cancer cells (pdOVCs) and a Patient Derived Xenograft (PDX), respectively. CIK were efficiently generated (48 fold median ex vivo expansion) from EOC patients; pdOVCs lines (n = 9) were successfully generated from metastatic ascites; the expression of CIK target molecules by pdOVC confirmed pre and post treatment in vitro with carboplatin. The results indicate that patient-derived CIK effectively killed autologous pdOVCs in vitro. Such intense activity was maintained against a subset of pdOVC that survived in vitro treatment with carboplatin. Moreover, CIK antitumor activity and tumor homing was confirmed in vivo within an EOC PDX model. Our preliminary data suggest that CIK are active in platinum resistant ovarian cancer models and should be therefore further investigated as a new therapeutic option in this extremely challenging setting.


Asunto(s)
Carcinoma Epitelial de Ovario/terapia , Células Asesinas Inducidas por Citocinas/inmunología , Inmunoterapia/métodos , Neoplasias Ováricas/terapia , Anciano , Animales , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Carboplatino/farmacología , Carboplatino/uso terapéutico , Carcinoma Epitelial de Ovario/sangre , Carcinoma Epitelial de Ovario/inmunología , Carcinoma Epitelial de Ovario/patología , Línea Celular Tumoral , Resistencia a Antineoplásicos , Femenino , Humanos , Ratones , Persona de Mediana Edad , Neoplasias Ováricas/sangre , Neoplasias Ováricas/inmunología , Neoplasias Ováricas/patología , Ovario/patología , Cultivo Primario de Células , Ensayos Antitumor por Modelo de Xenoinjerto
2.
BAG, J. basic appl. genet. (Online) ; 30(1): 25-33, June 2019. graf, tab
Artículo en Español | LILACS-Express | LILACS | ID: biblio-1089061

RESUMEN

El maíz (Zea mays L.) posee un genoma complejo y una amplia diversidad genética. La información de caracteres fenotípicos y marcadores moleculares en su conjunto provee una mejor descripción e interpretación de la variabilidad genética. El objetivo del trabajo fue estimar la diversidad genética y caracterizar fenotípicamente un panel de 291 líneas de maíz de CIMMYT. Las líneas corresponden a ocho grupos establecidos de acuerdo a su adaptación ambiental y origen geográfico. Éstas se evaluaron fenotípicamente por medio de nueve caracteres agro-morfológicos en tres ambientes del sur de la provincia de Córdoba, Argentina. El intervalo antesis-estigma (IAE) presentó la mayor variabilidad fenotípica. El 40% de las líneas de maíz registraron un IAE menor a cinco días, indicando buena adaptación a los ambientes de evaluación. La estructura poblacional dada por los subgrupos de adaptación ambiental es sólo un factor menor que contribuye a la variabilidad fenotípica del panel estudiado. El análisis de componentes principales (ACP) permitió obtener el ordenamiento fenotípico y el genotípico, mientras que el análisis de procrustes generalizado indicó un consenso del 60% entre ambos ordenamientos para el total de líneas. El consenso entre el ordenamiento obtenido con caracteres agro-morfológicos y con marcadores moleculares indica desequilibrio de ligamiento entre los SNPs y los genes que controlan los caracteres agro-morfológicos. Los resultados muestran una amplia diversidad genética en el germoplasma evaluado, lo que sugiere que esta colección de líneas es un recurso importante para impulsar ganancias genéticas futuras en los programas de mejoramiento de maíz de Argentina.


CIMMYT maize inbred lines (CMLs) are freely distributed to breeding programs around the world. Better information on phenotypic and genotypic diversity may provide guidance to breeders on how to use more efficiently the CMLs in their breeding programs. In this study a group of 291 CIMMYT maize inbred lines, was phenotyped by nine agro-morphological traits in south Córdoba, Argentina and genotyped using 18,082 SNPs. Based on the geographic information and the environmental adaptation, 291 CMLs were classified into eight subgroups. Anthesis-silking interval (IAE) was the trait with higher phenotypic diversity. A 40% of maize inbred lines, with IAE less than five days, show a good adaptation to growing conditions in south Córdoba, Argentina. The low phenotypic variation explained by environmental adaptation subgroups indicates that population structure is only a minor factor contributing to phenotypic diversity in this panel. Principal component analysis (ACP) allowed us to obtain phenotypic and genotypic orderings. Generalized procrustes analysis (APG) indicated a 60% consensus between both data type from the total panel of maize lines. In each environmental adaptation subgroup, the APG consensus was higher. This result, which might indicate linkage disequilibrium between SNPs markers and the genes controlling these agro-morphological traits, is promising and could be used as an initial tool in the identification of Quantitative Trait Loci (QTL). Information on genetic diversity, population structure and phenotypic diversity in local environments will help maize breeders to better understand how to use the current CIMMYT maize inbred lines group.

3.
Nat Commun ; 9(1): 2056, 2018 05 21.
Artículo en Inglés | MEDLINE | ID: mdl-29785000

RESUMEN

The original version of this Article contained an error in the last sentence of the second paragraph of the 'Atmospheric rarefaction effects' section of the Results, which incorrectly read 'The other one emulates the rarefied, CO2-rich Martian atmosphere (µâ™‚ = 1.3 × 10-5 N s m-2) at 6.9 mbar and 210 K, which gives ρ♂ = 1.6 × 10-12 kg m-3.' The correct version states 'ρ♂ = 1.6 × 10-2 kg m-3' in place of 'ρ♂ = 1.6 × 10-12 kg m-3'. This has been corrected in both the PDF and HTML versions of the Article.

4.
Nat Commun ; 9(1): 1676, 2018 04 26.
Artículo en Inglés | MEDLINE | ID: mdl-29700300

RESUMEN

Self-induced electricity, including lightning, is often observed in dusty atmospheres. However, the physical mechanisms leading to this phenomenon remain elusive as they are remarkably challenging to determine due to the high complexity of the multi-phase turbulent flows involved. Using a fast multi-pole method in direct numerical simulations of homogeneous turbulence laden with hundreds of millions of inertial particles, here we show that mesoscopic electric fields can be aerodynamically created in bi-disperse suspensions of oppositely charged particles. The generation mechanism is self-regulating and relies on turbulence preferentially concentrating particles of one sign in clouds while dispersing the others more uniformly. The resulting electric field varies over much larger length scales than both the mean inter-particle spacing and the size of the smallest eddies. Scaling analyses suggest that low ambient pressures, such as those prevailing in the atmosphere of Mars, increase the dynamical relevance of this aerodynamic mechanism for electrical breakdown.

5.
Gynecol Oncol ; 138(3): 627-33, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26100858

RESUMEN

OBJECTIVE: The treatment of platinum resistant/refractory epithelial ovarian cancer (EOC) is a challenge for oncologists. One of the most utilized drugs in these patients is pegylated liposomal doxorubicin (PLD). As PLD is active only in a small subset of patients and causes side effects, selection of responsive patients is an unmet need and might be guided by the status of the DNA topoisomerase II alpha (TOP2A) that is poisoned by the drug. METHODS: From 176 ovarian cancers treated in three institutions, we selected 38 patients treated with PLD monotherapy as second/third line of treatment. TOP2A gene copies were measured using Fluorescent In Situ Hybridization (FISH) and expression evaluated using immunohistochemistry. Patients' derived xenografts (PDXs) of ovarian cancers were used to assess the correlation between TOP2A protein expression and response to PLD. RESULTS: Clinical data showed that TOP2A gene gain that is paralleled by increased expression of the protein, was associated with a higher probability of clinical benefit from PLD. Treatment of PDXs demonstrated that only xenografts showing a high percentage of TOP2A expressing cells underwent tumor shrinkage when treated with PLD. CONCLUSIONS: These data show that TOP2A gene gain and protein over-expression might predict activity of PLD in platinum resistant/refractory EOC.


Asunto(s)
Antibióticos Antineoplásicos/farmacología , Antígenos de Neoplasias/genética , ADN-Topoisomerasas de Tipo II/genética , Proteínas de Unión al ADN/genética , Doxorrubicina/análogos & derivados , Neoplasias Glandulares y Epiteliales/tratamiento farmacológico , Neoplasias Glandulares y Epiteliales/genética , Neoplasias Ováricas/tratamiento farmacológico , Neoplasias Ováricas/genética , Animales , Carcinoma Epitelial de Ovario , Supervivencia sin Enfermedad , Doxorrubicina/farmacología , Resistencia a Antineoplásicos , Femenino , Dosificación de Gen , Humanos , Ratones , Ratones Endogámicos NOD , Ratones SCID , Persona de Mediana Edad , Neoplasias Glandulares y Epiteliales/enzimología , Neoplasias Ováricas/enzimología , Proteínas de Unión a Poli-ADP-Ribosa , Polietilenglicoles/farmacología , Distribución Aleatoria , Ensayos Antitumor por Modelo de Xenoinjerto
6.
Eur Rev Med Pharmacol Sci ; 13(1): 63-5, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19364087

RESUMEN

Takayasu arteritis (TA) is a chronic inflammatory disease of large arteries which progressively develop stenosis, occlusion or aneurismal degeneration. Proinflammatory cytokines and, among these, tumor necrosis factor-alpha (TNF-alpha) are increased and play a pathogenetic role in the development of disease. Conventional therapy often fails to determine clinical remission and, in these cases, pathogenetic strategies with anti-TNF-alpha drugs have been proposed. Infliximab is a human-murine chimeric monoclonal antibody that specifically binds to and neutralizes soluble TNF-alpha. It is an effective treatment for rheumatoid arthritis, spondyloarthritis, Crohn's disease and ulcerative colitis and it has been recently proposed for the treatment of TA in patients refractory to conventional therapy. Here we report the case of a patient affected by Takayasu arteritis unresponsive to conventional therapy who was then treated with infliximab and obtained a clinical remission of the disease.


Asunto(s)
Antiinflamatorios/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Arteritis de Takayasu/tratamiento farmacológico , Resistencia a Medicamentos , Femenino , Humanos , Infliximab , Persona de Mediana Edad , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores
7.
Clin Exp Med ; 8(3): 171-3, 2008 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-18791691

RESUMEN

Good syndrome (GS) is a rare adult-onset immunodeficiency disease characterised by hypogammaglobulinaemia and thymoma. Here we describe a 72-year-old male patient who was diagnosed with GS when he was 62, after a two-year history of recurrent respiratory infections. A chest CT scan showed a mediastinal mass which was surgically removed; its histology revealed a thymoma. The patient was hypogammaglobulinaemic and his clinical condition dramatically improved after starting an appropriate dosage of IVIG. Two years ago he developed a normochromic normocytic anaemia requiring several transfusions. A bone marrow biopsy revealed a myelodysplastic syndrome. The patient started cyclosporine and the anaemia gradually improved, achieving transfusion independence.


Asunto(s)
Síndromes de Inmunodeficiencia/diagnóstico , Síndromes Mielodisplásicos/diagnóstico , Anciano , Ciclosporina/uso terapéutico , Humanos , Síndromes de Inmunodeficiencia/complicaciones , Masculino , Síndromes Mielodisplásicos/complicaciones , Síndromes Mielodisplásicos/tratamiento farmacológico
8.
Clin Exp Immunol ; 151(3): 407-13, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18234053

RESUMEN

Graft-versus-host disease (GVHD) is a major complication of allogeneic bone marrow transplantation. Extracorporeal photochemotherapy (ECP) has been introduced as an alternative treatment for GVHD refractory to conventional immunosuppressive treatment, although its mechanism of action is not yet clear. We investigated, in seven GVHD patients, the effects of ECP on dendritic cell maturation and cytokine production in an in vitro model that could mimic the potential in vivo effect of reinfusion of ECP-treated peripheral blood mononuclear cells. The model was based on co-culture of ECP-treated lymphocytes with monocyte-derived dendritic cells (DCs) of the same patient. We found that the co-culture of ECP-treated lymphocytes with immature DCs reduced CD54, CD40 and CD86 mean fluorescence intensity (MFI) significantly after lipopolysaccharide (LPS) stimulation, without affecting human leucocyte antigen D-related and CD80 MFI. In the same co-culture model, DCs produced increased amounts of interleukin (IL)-10 when co-cultured with ECP-treated lymphocytes and stimulated with LPS, while IL-12 and tumour necrosis factor-alpha production were not affected. These results suggest that reinfusion of large numbers of autologous apoptotic lymphocytes is significant for the therapeutic outcome of ECP through down-regulation of co-stimulatory molecules on DCs, inducing non-fully mature DCs with a low signal 2 and up-regulation of IL-10, which is an immunosuppressive cytokine.


Asunto(s)
Células Dendríticas/efectos de los fármacos , Enfermedad Injerto contra Huésped/tratamiento farmacológico , Enfermedad Injerto contra Huésped/inmunología , Interleucina-10/biosíntesis , Fotoféresis , Enfermedad Aguda , Adulto , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/inmunología , Células Cultivadas , Enfermedad Crónica , Técnicas de Cocultivo , Células Dendríticas/inmunología , Femenino , Humanos , Inmunofenotipificación , Terapia de Inmunosupresión/métodos , Interleucina-12/biosíntesis , Lipopolisacáridos/inmunología , Linfocitos/inmunología , Masculino , Persona de Mediana Edad
9.
Eur J Clin Invest ; 37(9): 742-5, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17696965

RESUMEN

BACKGROUND: Inflammatory and/or immune activation occurs both in animal models (twitcher mice) and in the brain of patients with Globoid cell leukodystrophy (GLD) or Krabbe's disease (KD). In this study we evaluated in vitro the cytokine profile of KD patients and the effect of psychosine, the toxic metabolite which plays a role in the demyelination process in these patients. MATERIALS AND METHODS: We studied cytokine production by peripheral blood mononuclear cells (PBMCs) isolated from four KD patients, diagnosed on the basis of clinical criteria. Cells were cultured and stimulated with appropriate agents and the supernatants collected before and after the addition of psychosine. Tumour necrosis factor-alpha (TNF-alpha), interleukin-8 (IL-8) and monocyte chemoattractant factor (MCP)-1) production was evaluated (ELISA method) and compared with a group of 10 normal subjects. RESULTS: We found a significant increase of TNF-alpha release by PBMCs of KD patients compared with healthy subjects; TNF-alpha production was significantly increased after LPS addition. Psychosine was able to induce a further significant increase (P < 0.05) only in cells obtained from KD patients and not from control subjects. No changes were found in IL-8 and MCP-1 production. CONCLUSIONS: The increased TNF-alpha production permits us to confirm the presence of an inflammatory-immune stimulus in KD patients, which may be induced and potentiated by the pathogenetic metabolite psychosine.


Asunto(s)
Citocinas/metabolismo , Leucodistrofia de Células Globoides/etiología , Psicosina/efectos adversos , Factor de Necrosis Tumoral alfa/metabolismo , Adulto , Animales , Modelos Animales de Enfermedad , Femenino , Humanos , Leucodistrofia de Células Globoides/metabolismo , Masculino , Ratones , Resultado del Tratamiento
10.
Oncogene ; 26(7): 1078-87, 2007 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-16953230

RESUMEN

Overexpressed or activated hepatocyte growth factor receptor, encoded by the MET proto-oncogene, was found in the majority of colorectal carcinomas (CRCs), whose stepwise progression to malignancy requires transcriptional activation of beta-catenin. We here demonstrate that a functional crosstalk between Met and beta-catenin signaling sustains and increases CRC cell invasive properties. Hepatocyte growth factor (HGF) stimulation prompts beta-catenin tyrosine phosphorylation and dissociation from Met, and upregulates beta-catenin expression via the phosphatidylinositol 3-kinase pathway in conditions that mimic those found by the invading and metastasizing cells. Additionally, a transcriptionally active form of beta-catenin, known to be oncogenic, enhances Met expression. Furthermore, HGF treatment increases the activity of the beta-catenin-regulated T-cell factor transcription factor in cells expressing the wild-type or the oncogenic beta-catenin. In the mirror experiments, either Met or beta-catenin knocking down also reduces their protein level. In biological assays, beta-catenin knocking down abrogates the HGF-induced motile phenotype, whereas active beta-catenin fosters ligand-independent cell scattering. Met and beta-catenin also cooperate in promoting entry into the cell cycle and in protecting cells from apoptosis. In conclusion, Met and beta-catenin pathways are mutually activated in CRC cells. This might generate a self-amplifying positive feedback loop resulting in the upregulation of the invasive growth properties of CRC cells.


Asunto(s)
Proliferación Celular , Neoplasias Colorrectales/metabolismo , Neoplasias Colorrectales/patología , Retroalimentación Fisiológica/fisiología , Proteínas Proto-Oncogénicas c-met/fisiología , beta Catenina/fisiología , Comunicación Celular/fisiología , Supervivencia Celular/fisiología , Células HCT116 , Humanos , Invasividad Neoplásica , Proto-Oncogenes Mas , Proteínas Proto-Oncogénicas c-met/genética , beta Catenina/genética
11.
Int J Immunopathol Pharmacol ; 19(2): 391-7, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16831305

RESUMEN

Mycobacterium avium complex is a facultative intracellular pathogen that can cause pulmonary disease in immunocompromised individuals. Dendritic cells (DCs) play a central role in protective immunity against mycobacteria. Mycobacterium avium complex infects DCs but does not impair in vitro infected monocytes differentiation into DCs. A 54-year old woman affected by chronic graft-versus-host-disease (cGVHD) was referred to our Division of Dermatology. Immature DCs were generated from her monocytes. One week later she was hospitalized due to a lung infection with Mycobacterium avium complex. Monocyte-derived DCs during Mycobacterium avium infection expressed low levels of CD1a and CD80 as determined by flow cytometry. They also expressed high levels of CD83 and CD86, and when stimulated with LPS for 24 hrs they slightly up-regulated CD83 and did not produce IL12. When monocyte-derived DCs were obtained from the patient after having recovered from the Mycobacterium avium complex infection, they expressed normal levels of CD1a and CD80 and were negative both for CD83 and for CD86. IL12 production in response to LPS was restored. Inhibition of DC maturation by the in vivo infection with Mycobacterium avium may be an immune-evasion mechanism used by the pathogen because incompletely matured DCs may not activate effector T cells efficiently in vivo.


Asunto(s)
Células Dendríticas/fisiología , Monocitos/fisiología , Infección por Mycobacterium avium-intracellulare/inmunología , Antígenos CD/inmunología , Antígenos CD1/inmunología , Diferenciación Celular/fisiología , Enfermedad Crónica , Citocinas/biosíntesis , Femenino , Citometría de Flujo , Enfermedad Injerto contra Huésped/inmunología , Humanos , Inmunoglobulinas/inmunología , Interleucina-12/biosíntesis , Glicoproteínas de Membrana/inmunología , Persona de Mediana Edad , Fenotipo , Antígeno CD83
12.
Clin Exp Med ; 6(1): 38-44, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16550343

RESUMEN

The aim of this study was to evaluate the presence of an imbalance between proinflammatory and anti-inflammatory mediators in patients affected by acute coronary syndromes (ACS). We considered two groups of 26 and 28 patients with acute myocardial infarction (AMI) and unstable angina (UA) respectively, compared with a group of 30 patients with stable angina and 30 healthy volunteers. We evaluated the production in cultured and stimulated lymphomonocytes of interferon (IFN)gamma and tumour necrosis factor (TNF)alpha, which are well known to possess proinflammatory effects, and of interleukin (IL)10, which has been shown to have a protective anti-inflammatory activity. We also assessed the clinical characteristics of groups and, particularly, we evaluated the circulating levels of C-reactive protein (hs-CRP). We found a significant increase of IFNgamma and TNFalpha production (P<0.01) and a significant decrease of IL10 production (P<0.05) in cultures of lymphomonocytes taken from patients with AMI and UA compared with SA patients and controls. No significant changes where found between AMI and UA patients and SA patients and controls. Circulating levels of hs-CRP were significantly increased (P<0.01) in patients with ACS compared with the other control groups. Our data showed an increased production of proinflammatory mediators in ACS that may be detectable both in circulating blood and in cell cultures where it is possible to evaluate in a better way the functional state of cells; this finding was associated with a reduced production of the antiinflammatory cytokine IL10. In conclusion, a relevant imbalance is present in ACS and this fact could contribute to plaque instability and clinical manifestations.


Asunto(s)
Angina Inestable/inmunología , Interferón gamma/metabolismo , Interleucina-10/metabolismo , Monocitos/inmunología , Infarto del Miocardio/inmunología , Factor de Necrosis Tumoral alfa/metabolismo , Enfermedad Aguda , Anciano , Angina Inestable/metabolismo , Proteína C-Reactiva/metabolismo , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Persona de Mediana Edad , Monocitos/metabolismo , Infarto del Miocardio/metabolismo
13.
Int J Cardiol ; 105(3): 355-6, 2005 Dec 07.
Artículo en Inglés | MEDLINE | ID: mdl-16216352

RESUMEN

The aim of this study was to show the presence of an imbalance between pro-inflammatory and anti-inflammatory mediators in patients affected by acute coronary syndromes (ACS). We evaluated the production in cultured and stimulated lymphomonocytes of interferon (IFN)gamma and tumor necrosis factor (TNF)alpha, which are well known to possess pro-inflammatory effects, and of interleukin (IL)10, which has been shown to have a protective anti-inflammatory activity, in two groups of 30 patients affected by acute myocardial infarction (AMI) and unstable angina (UA), compared with two equivalent groups of patients with stable angina (SA) and of healthy volunteers. We found a significant increase of IFNgamma and TNFalpha production (p<0.01) and a significant decrease of IL-10 production (p<0.01) in cultures of lymphomonocytes taken from patients with AMI and UA compared with SA patients and controls. No significant changes were found between AMI and UA patients and SA patients and controls. We conclude that a relevant imbalance in cytokine release is present in ACS, markedly favoring pro-inflammatory effects.


Asunto(s)
Angina Inestable/inmunología , Interferón gamma/biosíntesis , Interleucina-10/biosíntesis , Monocitos/inmunología , Infarto del Miocardio/inmunología , Factor de Necrosis Tumoral alfa/biosíntesis , Enfermedad Aguda , Humanos
14.
Artículo en Inglés | MEDLINE | ID: mdl-16095891

RESUMEN

Iloprost, a stable prostacyclin analogue, regulates expression of genes that are involved in inflammation and in cell growth and inhibits the in vitro production of cytokines. We evaluated the effect of an in vivo weekly iloprost treatment on TNF-alpha and IL6 monocyte production (evaluated by ELISA), on monocyte apoptosis (Annexin V/uptake of propidium iodide by flow cytometry) and on peripheral blood mononuclear cell (PBMC) TNF-alpha receptors (TNF-RI and TNF-RII) mRNA expression (RT-PCR) in 14 atherosclerotic critical limb ischemia patients. PBMC were stimulated with LPS for 24h. TNF-alpha production was significantly reduced by iloprost whereas IL6 production was not affected. Iloprost did not accelerate monocyte apoptosis. TNF-RI mRNA expression was not modified by iloprost, whereas TNF-RII mRNA expression was significantly reduced. Our data show that iloprost may have anti-inflammatory effects in addition to the well-known vasodilatatory and anti-aggregant ones.


Asunto(s)
Iloprost/uso terapéutico , Interleucina-6/metabolismo , Isquemia/tratamiento farmacológico , Extremidad Inferior/irrigación sanguínea , Receptores Tipo II del Factor de Necrosis Tumoral , Factor de Necrosis Tumoral alfa , Anciano , Anciano de 80 o más Años , Antiinflamatorios/uso terapéutico , Apoptosis/efectos de los fármacos , Células Cultivadas , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Isquemia/metabolismo , Masculino , Monocitos/efectos de los fármacos , Monocitos/metabolismo , ARN Mensajero/genética , ARN Mensajero/metabolismo , Receptores Tipo I de Factores de Necrosis Tumoral/genética , Receptores Tipo I de Factores de Necrosis Tumoral/metabolismo , Receptores Tipo II del Factor de Necrosis Tumoral/antagonistas & inhibidores , Receptores Tipo II del Factor de Necrosis Tumoral/genética , Receptores Tipo II del Factor de Necrosis Tumoral/metabolismo , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Factor de Necrosis Tumoral alfa/metabolismo
15.
Br J Dermatol ; 153(1): 59-65, 2005 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16029327

RESUMEN

BACKGROUND: Chronic graft-versus-host disease (cGVHD) is a major complication of allogeneic bone marrow transplantation. Extracorporeal photopheresis (ECP) has recently been introduced as an alternative treatment for cases of cGVHD refractory to conventional immunosuppressive treatment, but its mechanism of action is not yet clear. OBJECTIVES: To investigate in seven patients with cGVHD the effects of ECP on resistance of monocytes to apoptosis and on monocyte cytokine production. METHODS: We designed an in vitro model that could mimic the potential in vivo effect of reinfusion of peripheral blood mononuclear cells treated by ECP. The model was based on coculture of ECP-treated lymphocytes with untreated monocytes from the same patient. RESULTS: ECP did not accelerate spontaneous apoptosis of monocytes. However, ECP-treated monocytes produced increased amounts of interleukin (IL)-12. In contrast, IL-12 production by monocytes did not increase in cocultures, but IL-10 production was upregulated. CONCLUSIONS: These results suggest that reinfusion of large numbers of autologous apoptotic lymphocytes is significant for the therapeutic outcome of ECP through upregulation of IL-10, which is an immunosuppressive cytokine.


Asunto(s)
Enfermedad Injerto contra Huésped/tratamiento farmacológico , Interleucina-10/biosíntesis , Interleucina-12/biosíntesis , Monocitos/inmunología , Fotoféresis , Adulto , Apoptosis , Células Cultivadas , Enfermedad Crónica , Técnicas de Cocultivo , Femenino , Enfermedad Injerto contra Huésped/inmunología , Humanos , Linfocitos/inmunología , Masculino , Monocitos/patología
16.
Nutr Metab Cardiovasc Dis ; 15(1): 56-64, 2005 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-15871852

RESUMEN

BACKGROUND AND AIM: Microvascular damage of coronary bed has been considered the main pathogenetic factor of cardiac syndrome X (chest pain, exercise-induced ischemic ST-segment changes and angiographically normal coronary arteries). Previous studies have demonstrated that vascular abnormalities are not confined to the heart, suggesting a peripheral vascular dysfunction. On the hypothesis of a generalized microvascular disturbance in cardiac syndrome X, we performed a morphologic and functional study of systemic microcirculation in patients with syndrome X compared to normal subjects. METHODS AND RESULTS: Microvessels were evaluated with intravital videocapillaroscopy (VCP) executed in peripheral and conjunctival observation sites which explore micro and paramicrocirculation; biohumoral study included markers of inflammation and of endothelial function, coagulative-fibrinolytic system and lipid metabolism. Videocapillaroscopy showed several morphologic changes (present in high percent of patients with syndrome X and not in controls) and significant quantitative alterations (capillary density, granular flow score, alterations of vessel profile, length of capillary loop branches and of arteriole/venule diameter) which indicated a severe alteration of whole vessel structure and an important rearrangement of microvascular disposition. In a similar way, the humoral study showed some significant changes of endothelial (vWF, ICAM-1, E-sel, PAI-1), inflammatory (C-reactive protein (CRP), fibrinogen) and metabolic factors (HDL-chol) which are commonly associated with inflammatory response. CONCLUSIONS: We conclude that patients with cardiac syndrome X exhibited some structural and functional alterations of systemic microvasculature; the pattern is similar to that detected in systemic inflammatory diseases and suggests a vascular lesion of inflammatory type. The same changes could be operating also in coronary microvessels of patients with syndrome X.


Asunto(s)
Angina de Pecho/fisiopatología , Circulación Coronaria/fisiología , Vasos Coronarios/patología , Microcirculación/fisiopatología , Angina Pectoris Variable/fisiopatología , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Angioscopía Microscópica , Microscopía por Video , Persona de Mediana Edad , Síndrome
17.
Int Angiol ; 24(1): 64-9, 2005 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15877001

RESUMEN

AIM: Iloprost, usually administered through intravenous infusion for 6 hours per day for at least 21 days, is the main medical treatment for critical limb ischemia in patients unsuitable for surgical or endovascular approach. We evaluated the tolerance and the short-term and long-term effects of a single 1-week treatment in critical limb ischemia patients. METHODS: Twenty-nine patients in Leriche-Fontaine III and IV stage were treated with iloprost infusions for 16 hours per day for 7 days, achieving a maximal dose of 1.5 ng/kg/min. Tolerance and clinical assessment after treatment discontinuation and after 1 and 6 months were recorded; clinical evaluation (rest pain, trophic lesions), ankle/brachial pressure index (ABPI) and treadmill exercise test were performed before, immediately after treatment and after 1 and 6 months. RESULTS: No discontinuation of treatment occurred because of intolerance to iloprost. At the end of the treatment 69% of patients were responders, 55.2% at 1 month, 37.9% after 6 months. ABPI and treadmill maximum walking distance were improved by the treatment at every timepoint. After 6 months 10.3% mortality and 3.4% major amputation rates were recorded. There was a higher percentage of non-responders amongst women vs men, in diabetic patients vs non diabetic and in stage IV patients vs stage III. CONCLUSIONS: One-week treatment with iloprost is safe and effective in both Leriche-Fontaine stage III and IV patients. Clinical effects are persistent over time, often lasting up to the 6th month, similarly to the commonly used 28-day treatment, with clear implications in terms of patient's compliance and medical cost containment.


Asunto(s)
Iloprost/administración & dosificación , Vasodilatadores/administración & dosificación , Anciano , Anciano de 80 o más Años , Prueba de Esfuerzo , Femenino , Humanos , Infusiones Intravenosas , Isquemia , Masculino , Persona de Mediana Edad
18.
Int J Cardiol ; 95(2-3): 269-74, 2004 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15193831

RESUMEN

BACKGROUND: Hydroxymethyl-glutaryl-CoA-reductase inhibitors (statins) reduce cardiovascular events by cholesterol lowering as well as non-lipid related actions. Among them, the modulation of fibrinolysis could play a relevant role in vascular protection. Atorvastatin is able of reducing platelet activity and thrombin generation before low-density lipoprotein cholesterol (LDL-C) decrease in hypercholesterolemic subjects in which coagulation and fibrinolysis are linked by the activation of thrombin activable fibrinolysis inhibitor (TAFI). The aim of our study was to evaluate whether atorvastatin could modulate fibrinolysis by interactions with endothelial mechanisms and thrombin generation. METHODS: Forty-four pure hypercholesterolemic subjects (26 M, 18 F, mean age 52.7+/-13.7, LDL-C 194.8+/-9.3t mg/dl) were evaluated for plasmin-antiplasmin complexes (PAP), tissue-plasminogen acivator (t-PA) and its inhibitor (PAI-1) (ELISA), TAFI activity (HPLC), platelet P-selectin (P-sel) (cytofluorymetric detection), platelet-dependent thrombin generation (PDTG, coagulative-chromogenic method) and lipid profile at baseline and after 7, 14, 28 and 90 days of atorvastatin (10 mg/die) treatment. RESULTS: PAP were significantly reduced at baseline in hypercholesterolemic versus control subjects (P<0.05) and were related to P-sel (P<0.01), PDTG (P<0.01) and its inhibitor (PAI-1) after venous occlusion (VO) (P<0.05). Atorvastatin induced a significant increase of PAP at T(2) related to modifications of P-sel (P<0.01) and PDTG (P<0.01) before significant LDL-C reduction (P=0.132). PAI-1 was significantly changed at T(3) with relation to LDL-C (P<0.01), Von Willebrand factor (VWF) (P<0.01) and sE-sel (P<0.05). CONCLUSIONS: The profibrinolytic activity of atorvastatin in hypercholesterolemic subjects is related, initially, to the positive effects exerted on platelet function and thrombin generation which can modulate fibrinolysis by TAFI activity.


Asunto(s)
Fibrinólisis/efectos de los fármacos , Ácidos Heptanoicos/farmacología , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Hipercolesterolemia/tratamiento farmacológico , Pirroles/farmacología , Adulto , Análisis de Varianza , Atorvastatina , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estadísticas no Paramétricas
19.
Br J Dermatol ; 150(6): 1055-60, 2004 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15214889

RESUMEN

Chronic graft-versus-host disease (GvHD) affects 50% of long-term bone marrow transplant survivors and remains a cause of major long-term morbidity in these patients despite aggressive therapy. Extracorporeal photochemotherapy (ECP), considered as an effective treatment for patients with erythrodermic cutaneous T-cell lymphoma (CTCL), has recently been used successfully in the treatment of GvHD. One of the most intriguing aspects of ECP is its ability to induce two apparently opposite effects: activation of the immune system against neoplastic cells (as in CTCL) and downregulation of the activity of T-cell clones in autoimmune diseases (as in systemic sclerosis, systemic lupus erythematosus and pemphigus vulgaris) and autoallogeneic immune responses (as in GvHD and allograft rejection). Only a better and more complete understanding of the various mechanisms involved will enable this interesting new therapy to be made more effective and selective.


Asunto(s)
Enfermedad Injerto contra Huésped/terapia , Fotoféresis , Apoptosis , Trasplante de Médula Ósea , Enfermedad Crónica , Células Dendríticas/inmunología , Enfermedad Injerto contra Huésped/inmunología , Humanos , Células Asesinas Naturales/inmunología , Activación de Linfocitos , Linfocitos/inmunología , Linfoma Cutáneo de Células T/inmunología , Linfoma Cutáneo de Células T/terapia , Monocitos/patología , Monocitos/efectos de la radiación , Inmunología del Trasplante
20.
Clin Exp Med ; 3(4): 211-7, 2004 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15103511

RESUMEN

Common variable immunodeficiency (CVID) is the commonest symptomatic primary antibody deficiency syndrome. The predominant manifestation is hypogammaglobulinemia. CVID is characterized by recurrent bacterial infections, especially of the upper and lower respiratory airways, and is also associated with an increased incidence of autoimmune and neoplastic disorders. Most patients are diagnosed as adults and delay in the recognition of the disease is common. Several T and B cell defects have been described, although the underlying cause is still unknown.


Asunto(s)
Inmunodeficiencia Variable Común , Inmunodeficiencia Variable Común/diagnóstico , Inmunodeficiencia Variable Común/etiología , Inmunodeficiencia Variable Común/fisiopatología , Inmunodeficiencia Variable Común/terapia , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA